Biedroń-Machura Marta, Musialik Joanna, Sozańska Ewa, Zbroszczyk Miłosz, Baron Jan, Błońska-Fajfrowska Barbara, Pierzchała Władysław
Klinika Pneumonologii, Slaski Uniwersytet Medyczny, Centralny Szpital Kliniczny im K. Gibińskiego, Katowice.
Wiad Lek. 2012;65(4):232-8.
Pulmonary complications during standard therapy of chronic hepatitis C with pegylated interferon and ribavirin are rare but connected with wide spectrum of diseases from sarcoidosis to interstitial pneumonitis. The clinical course of that complications is often serious. In this paper, presentation of two patients with chronic hepatitis C with different anamnesis was shown. In the first case, without pulmonary burden, during therapy the features of pneumonitis were developed. In the second case, in patient with sarcoidosis, the antiviral therapy was carried out without important pulmonary aggravation. In reference to these observations and based on available literature, the pathogenetic mechanisms underlying pulmonary complications during this kind of therapy were discussed. Additionally, the scheme of pulmonary diagnostic proceeding in patients certified and then treated with peginterferon and ribawirin was proposed.
在使用聚乙二醇干扰素和利巴韦林对慢性丙型肝炎进行标准治疗期间,肺部并发症虽罕见,但与从结节病到间质性肺炎的多种疾病相关。这些并发症的临床病程往往较为严重。本文展示了两名具有不同病史的慢性丙型肝炎患者的情况。在第一个病例中,患者无肺部负担,在治疗期间出现了肺炎特征。在第二个病例中,患有结节病的患者在进行抗病毒治疗时未出现严重的肺部病情加重。参照这些观察结果并基于现有文献,讨论了此类治疗期间肺部并发症的发病机制。此外,还提出了对确诊后接受聚乙二醇干扰素和利巴韦林治疗的患者进行肺部诊断的流程方案。